Cotson10 mg

Cotson is a corticosteroid (glucocorticoid) used in both topical and systemic forms, depending on the condition being treated.

Established / FDA-approved uses

• Topical (cream, ointment, lotion): Relief of inflammation and itching associated with mild-to-moderate corticosteroid-responsive dermatoses such as eczema, atopic dermatitis, contact dermatitis, insect bite reactions, and mild plaque psoriasis.
• Systemic (oral tablet, injection): Replacement therapy in primary or secondary adrenocortical insufficiency (Addison's disease, pituitary-related adrenal insufficiency) and for acute adrenal crisis.
• Systemic: Management of severe allergic reactions and anaphylaxis (as an adjunct after epinephrine), severe asthma exacerbations, and acute exacerbations of chronic inflammatory/autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease, when a rapid-onset corticosteroid is required.
• Rectal (suppository/foam): Symptomatic relief of inflammation in ulcerative proctitis and hemorrhoids.
• Perioperative/stress dosing: Prevention and treatment of adrenal crisis ("stress-dose steroids") in patients with known adrenal insufficiency undergoing surgery, trauma, or severe illness.

Adjunct / combination-therapy uses

• As an adjunct to standard treatment (e.g., antihistamines, epinephrine, bronchodilators, disease-modifying agents) rather than as sole therapy for anaphylaxis, asthma, or autoimmune flares.
• Topical use on infected dermatoses only in combination with an appropriate antimicrobial agent, never as monotherapy for infected skin.

Off-label uses (commonly used, not formally FDA-labeled)

• Septic shock unresponsive to fluids and vasopressors (stress-dose corticosteroid support), based on critical-care guideline evidence.
• Congenital adrenal hyperplasia in some pediatric dosing regimens (specialist-guided).

The specific formulation, strength, and route are selected by the prescriber according to the condition being treated.

Hydrocortisone is available in Bangladesh and internationally in several dosage forms and strengths, including:

• Topical cream/ointment/lotion: 0.5%, 1%, and 2.5% Hydrocortisone
• Oral tablets: 5 mg, 10 mg, and 20 mg Hydrocortisone
• Injection (powder for reconstitution): Hydrocortisone sodium succinate, equivalent to 100 mg Hydrocortisone per vial (and higher-strength vials for hospital use)
• Rectal suppository/foam: for local anorectal use

Formulation and strength availability may vary by manufacturer and market; always check the product label for the exact composition of the specific brand dispensed.

Cotson is a synthetic form of cortisol, the glucocorticoid hormone naturally produced by the adrenal cortex. It belongs to the corticosteroid class of medicines and has anti-inflammatory, immunosuppressive, and anti-allergic properties.

Applied topically, Cotson reduces local skin inflammation, redness, and itching. Given systemically (orally or by injection), it is used both as hormone replacement in adrenal insufficiency and, at higher doses, to suppress inflammation and immune activity in a range of acute and chronic conditions.

Cotson is considered a short-acting (low-potency, short-duration) corticosteroid relative to synthetic derivatives such as prednisolone or dexamethasone, which makes it particularly suited to physiologic replacement dosing.

Corticosteroid (Glucocorticoid) — topical and systemic Cotson preparations

Hydrocortisone binds to intracellular glucocorticoid receptors, and the hormone-receptor complex translocates to the cell nucleus, where it regulates the transcription of genes involved in inflammation and immune function.

This results in:

• Reduced synthesis and release of inflammatory mediators (prostaglandins, leukotrienes, cytokines)
• Inhibition of phospholipase A2 via induction of lipocortin/annexin-1, reducing arachidonic acid release
• Decreased migration of leukocytes and macrophages to sites of inflammation
• Suppression of the immune response, including reduced lymphocyte proliferation and antibody production at higher systemic doses
• At physiologic replacement doses, restoration of normal effects of cortisol on carbohydrate, protein, and fat metabolism, and maintenance of cardiovascular and renal function via mineralocorticoid activity

Topically applied Hydrocortisone acts locally on skin tissue with limited systemic absorption at recommended doses, though absorption increases with higher potency formulations, occlusion, broken skin, and use in infants and young children.

• Topical: Wash and dry the affected area, then apply a thin film of Cotson and gently rub in. Wash hands after application unless the hands are the treated area. Avoid applying to the face, groin, or underarms unless specifically directed, and avoid occlusive dressings unless instructed by a physician.
• Oral tablets: Take with food or milk to reduce stomach upset. Take at the times instructed by the physician (often larger dose in the morning to mimic the body's natural cortisol rhythm).
• Injection: Administered by a healthcare professional intravenously or intramuscularly; the powder for injection must be reconstituted with the appropriate diluent immediately before use (see Reconstitution).
• Rectal: Insert the suppository or apply the foam/enema as directed, preferably after a bowel movement.

Do not use more Cotson, more often, or for longer than prescribed. Complete the course as directed by the physician and do not stop systemic therapy abruptly.

Cotson, particularly at systemic doses, has several clinically significant drug interactions:

• NSAIDs (e.g., ibuprofen, aspirin, diclofenac): Increased risk of gastrointestinal ulceration and bleeding when combined with systemic Cotson.
• Other immunosuppressants (e.g., methotrexate, azathioprine, biologics): Additive immunosuppression and increased risk of infection.
• Live or live-attenuated vaccines: Should generally be avoided during high-dose or prolonged systemic Cotson therapy due to reduced vaccine efficacy and risk of vaccine-related infection from immunosuppression.
• Antidiabetic medications (insulin, oral hypoglycemics): Systemic Cotson can raise blood glucose, requiring dose adjustment of diabetes medications.
• Warfarin and other anticoagulants: Cotson can alter anticoagulant response (increase or decrease INR); closer monitoring is advised.
• CYP3A4 inducers (e.g., rifampicin, phenytoin, carbamazepine): May reduce Cotson effectiveness by increasing its metabolism.
• CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): May increase Cotson levels and the risk of corticosteroid side effects.
• Diuretics (e.g., furosemide, thiazides): Additive risk of hypokalemia (low potassium) with systemic Cotson.

Always inform the physician or pharmacist of all other medicines, including over-the-counter drugs, vaccines, and herbal supplements, before starting Cotson.

Side effects of Cotson depend on the route, dose, and duration of use.

Topical use

• Common: local burning, stinging, itching, dryness, or redness at the application site
• With prolonged or excessive use: skin thinning (atrophy), stretch marks (striae), visible blood vessels (telangiectasia), delayed wound healing, acneiform eruptions, and (rarely) systemic absorption effects

Systemic use (oral/injectable)

• Common: increased appetite, weight gain, fluid retention, mood changes, insomnia, indigestion
• With prolonged use: hyperglycemia (raised blood sugar), hypertension, osteoporosis and increased fracture risk, adrenal suppression, increased susceptibility to infections, Cushingoid features (rounded face, central weight gain, thin skin, easy bruising), cataracts and glaucoma, muscle weakness, and mood or psychiatric disturbances
• Less common/serious: peptic ulceration, avascular necrosis of bone, growth suppression in children with prolonged use

Patients should seek medical attention for severe or persistent side effects, signs of infection, or mood/behavioral changes while on systemic Cotson.

Cotson should be used in pregnancy only if clearly needed, at the lowest effective dose and for the shortest duration, and only after the potential benefit to the mother has been weighed against potential risk to the fetus by the treating physician. Corticosteroids can cross the placenta; prolonged or high-dose systemic use in pregnancy has been associated with a small increased risk of oral clefts (first trimester) and effects on fetal growth or neonatal adrenal function with third-trimester exposure.

Cotson passes into breast milk in small amounts. Low-dose topical use and short courses of systemic therapy are generally considered compatible with breastfeeding when medically necessary, but a physician should be consulted, and if applied topically to the breast area, the area should be cleaned before nursing.

Pregnant or breastfeeding women should always consult their physician before starting or continuing Cotson.

• Adrenal suppression / abrupt withdrawal: Systemic Cotson used for more than a few days to weeks suppresses the body's own cortisol production. Stopping suddenly can precipitate a life-threatening adrenal (Addisonian) crisis; the dose must be tapered gradually under medical supervision.
• Infection risk: Cotson can mask signs of infection and increase susceptibility to new or latent infections (including tuberculosis, fungal, and viral infections); monitor closely, particularly with prolonged systemic use.
• Topical duration and area: Prolonged use, use over large body-surface areas, use under occlusive dressings, and use on thin-skinned areas (face, skin folds, genitals) increases the risk of skin atrophy and systemic absorption; this risk is higher in infants and young children due to a larger skin-surface-to-body-weight ratio.
• Metabolic effects: Monitor blood glucose in patients with diabetes and blood pressure in patients with hypertension during systemic therapy.
• Bone health: Long-term systemic use increases osteoporosis and fracture risk; calcium/vitamin D supplementation and bone density monitoring may be advised for prolonged courses.
• Live vaccines: Avoid administering live vaccines during high-dose systemic therapy (see Interactions).
• Psychiatric effects: May cause mood swings, insomnia, or, rarely, more severe psychiatric reactions; report significant mood or behavioral changes to the physician.
• Growth monitoring: In children on prolonged systemic therapy, growth should be monitored periodically.

Always take Cotson exactly as prescribed and inform the physician of the full medical history, including infections, diabetes, hypertension, osteoporosis, glaucoma, or psychiatric illness, before starting treatment.

Acute overdose with a single excessive dose of Cotson is rarely immediately life-threatening, but chronic excessive use can lead to significant Cushingoid effects (see Side Effects). Suspected overdose or accidental ingestion of a large amount, especially in a child, should be treated as a medical emergency.

If overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services. Do not attempt to manage a suspected overdose at home; treatment is supportive and directed by medical professionals based on the amount taken and the patient's symptoms.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze injectable solutions unless the product label specifically permits it.

Pediatric use

Cotson is used in children for approved indications (e.g., adrenal insufficiency, congenital adrenal hyperplasia replacement, short-course topical treatment of dermatitis), with dosing individualized by weight or body-surface area under specialist supervision. Children are more susceptible to skin thinning with topical use and to growth suppression with prolonged systemic use; treatment should use the lowest effective dose for the shortest duration, with growth monitored during prolonged courses.

Elderly

Elderly patients may be more susceptible to corticosteroid-related side effects such as osteoporosis, hypertension, glucose intolerance, skin fragility, and infection; use the lowest effective dose and monitor closely.

Renal impairment

No specific dose adjustment is generally required, but fluid retention and electrolyte effects should be monitored, as renal impairment may worsen fluid/electrolyte disturbances caused by systemic Cotson.

Hepatic impairment

Cotson does not require hepatic activation (unlike prednisone), so it may be preferred in significant hepatic impairment; nonetheless, monitor for enhanced corticosteroid effect since metabolism may still be reduced.

Duration of Cotson therapy is individualized by indication:

• Topical use for dermatitis/eczema: typically limited to 1–2 weeks per course unless the physician directs longer intermittent use for chronic conditions.
• Systemic use for acute allergic reactions or asthma flares: usually a short course of days.
• Replacement therapy for adrenal insufficiency: lifelong, at the lowest effective physiologic dose, with periodic medical review.
• Systemic use for chronic inflammatory/autoimmune conditions: duration determined by the treating specialist, generally the shortest duration and lowest dose that controls symptoms.

Do not extend or shorten the prescribed duration of systemic Cotson without consulting the physician, particularly after prolonged use, due to the risk of adrenal suppression.

Cotson sodium succinate powder for injection must be reconstituted immediately before use. Add the diluent supplied with, or specified for, the product (typically Bacteriostatic Water for Injection or 0.9% Sodium Chloride Injection) to the vial and gently swirl until the powder is fully dissolved and the solution is clear. Do not use if the reconstituted solution is cloudy or contains particulate matter. Use the reconstituted solution promptly and discard any unused portion according to the product's specific stability information; reconstitution and administration should be performed by a trained healthcare professional.

Corticosteroids; Glucocorticoids; Adrenal cortical steroids

Hydrocortisone exerts its effect by binding cytoplasmic glucocorticoid receptors; the activated receptor complex enters the cell nucleus and modulates transcription of genes controlling inflammatory and immune pathways. This suppresses the production of pro-inflammatory mediators (cytokines, prostaglandins, leukotrienes), reduces immune cell migration and activity, and, through induction of lipocortin-1, inhibits phospholipase A2 to limit the inflammatory cascade. Hydrocortisone also has mineralocorticoid activity, contributing to sodium and water retention and potassium excretion, which underlies part of its role in maintaining cardiovascular tone during physiologic replacement.

C

Cotson is used in pediatric patients for approved indications, including replacement therapy in adrenal insufficiency and congenital adrenal hyperplasia, and short courses of low-potency topical treatment for corticosteroid-responsive dermatoses. Dosing is weight- or body-surface-area-based and should be determined and monitored by a physician, ideally a pediatric specialist for endocrine indications.

Safety and efficacy of specific formulations and strengths in infants and young children should follow product labeling; for many higher-potency topical products and for prolonged systemic use, safety and efficacy in very young children have not been fully established, and use should be limited to the lowest effective dose for the shortest necessary duration, with monitoring of growth during prolonged systemic therapy.